natgillin/translations-raw huggingface dataset:
vesikulobulløst udslæt1, pustuløst udslæt1, urticaria1, misfarvning af huden (øget pigmentering)1, 4, makulopapuløst udslæt1, pruritus1 
vesiculobullous rash1, pustular rash1, urticaria1, skin discolouration (increased pigmentation)1, 4, maculopapular rash1, pruritus1
Rifampicin/Emtricitabin 
Rifampicin/Emtricitabine
Data for resistens, herunder krydsresistens, over for andre NNRTI'er hos patienter, der fik rilpivirinhydrochlorid i kombination med emtricitabin/tenofovirdisoproxil i fase III-studier (samlede data fra C209 og C215), og som oplevede virologisk svigt, er vist i Tabel 3 nedenfor. 
Resistance outcomes, including cross-resistance to other NNRTIs, in patients receiving rilpivirine hydrochloride in combination with emtricitabine/tenofovir disoproxil in Phase III studies (C209 and C215 pooled data) and experiencing virological failure, are shown in Table 3 below.
• Mindre hæmoglobin i blodet (et lavt antal røde blodlegemer) 
• Decrease in haemoglobin in your blood (low red blood cell count)
Eviplera bør anvendes med forsigtighed ved samtidig administration af lægemidler med en kendt risiko for torsades de pointes. 
Eviplera should be used with caution when co-administered with medicinal products with a known risk of Torsade de Pointes.
Begrænsede data fra kliniske studier støtter en dosering af Eviplera én gang dagligt hos patienter med let nedsat nyrefunktion (kreatininclearance (CrCl) 50-80 ml/min). 
Limited data from clinical studies support once daily dosing of Eviplera in patients with mild renal impairment (creatinine clearance (CrCl) 50-80 mL/min).
Hvis en patient kaster op mere end 4 timer efter at have taget Eviplera, skal patienten ikke tage en ny dosis af Eviplera, indtil den næste regelmæssigt skemalagte dosis. 
If a patient vomits more than 4 hours after taking Eviplera they do not need to take another dose of Eviplera until the next regularly scheduled dose.
Eviplera bør ikke indgives samtidig med adefovirdipivoxil. 
Eviplera should not be administered concomitantly with adefovir dipivoxil.
• Forhøjede leverenzym-niveauer i blodet 
• Increased levels of liver enzymes in the blood
Den mediane ændring i CD4-celletallet i analysen af patienter i behandling ved uge 48 var +17 x 106 celler/l. 
The median change in CD4+ cell count at week 48 was +17 x 106 cells/L, in the on-treatment analysis.
Patienter, som både er inficerede med hiv og HBV eller HCV Bivirkningsprofilen af emtricitabin, rilpivirinhydrochlorid og tenofovirdisoproxil hos patienter, som samtidigt er inficerede med hiv/HBV eller hiv/HCV lignede den, der observeres hos patienter, som kun er inficerede med hiv. 
The adverse reaction profile of emtricitabine, rilpivirine hydrochloride and tenofovir disoproxil in patients co-infected with HIV/HBV or HIV/HCV was similar to that observed in patients infected with HIV without co-infection.
Integrase strengoverførsels-hæmmere Raltegravir/Emtricitabin 
Integrase strand transfer inhibitors Raltegravir/Emtricitabine
Bioækvivalensen mellem én Eviplera filmovertrukken tablet og en emtricitabin 200 mg hård kapsel, en rilpivirin (som hydrochlorid) 25 mg filovertrukket tablet og en tenofovirdisoproxil 245 mg filmovertrukken tablet blev fastlagt efter indgivelse af en enkelt dosis hos ikke-fastende, raske forsøgspersoner. 
The bioequivalence of one Eviplera film-coated tablet with one emtricitabine 200 mg hard capsule, one rilpivirine (as hydrochloride) 25 mg film-coated tablet and one tenofovir disoproxil 245 mg film-coated tablet was established following single dose administration to fed, healthy subjects.
I et studie med raske personer har supraterapeutiske doser af rilpivirin (75 mg én gang dagligt og 300 mg én gang dagligt) vist sig at forlænge QTc-intervallet på EKG'et (se pkt. 
In a study of healthy subjects, supratherapeutic doses of rilpivirine (75 mg once daily and 300 mg once daily) have been shown to prolong the QTc interval of the ECG (see section 5.1).
• Kontakt Deres læge før De tager dette lægemiddel, hvis lægen har fortalt Dem, at De ikke tåler visse sukkerarter. 
• If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
I denne analyse var de NNRTIresistensassocierede mutationer, der hyppigst blev udviklet hos disse patienter: V90I, K101E, E138K/Q, V179I, Y181C, V189I, H221Y og F227C. 
In this analysis, the NNRTI resistance-associated mutations that developed most commonly in these patients were: V90I, K101E, E138K/Q, V179I, Y181C, V189I, H221Y and F227C.
Fås i pakninger, der indeholder 1 tabletbeholder med 30 filmovertrukne tabletter og pakninger indeholdende 90 (3 tabletbeholdere med 30) filmovertrukne tabletter. 
The following pack sizes are available: outer cartons containing 1 bottle of 30 film-coated tablets and outer cartons containing 90 (3 bottles of 30) film-coated tablets.
• knogleproblemer 
• bone problems
Da det er mere sandsynligt, at ældre patienter har nedsat nyrefunktion, skal der udvises forsigtighed ved behandling af ældre patienter med Eviplera (se pkt. 
Elderly patients are more likely to have decreased renal function, therefore caution should be exercised when treating elderly patients with Eviplera (see section 4.4).
Hos kvinder, der fik rilpivirin 25 mg én gang dagligt i 2. trimester af graviditeten, var de intraindividuelle gennemsnitlige Cmax, AUC24h og Cmin værdier for total rilpivirin henholdsvis 21 %, 29 % og 35 % lavere sammenlignet med postpartum. 
In women receiving rilpivirine 25 mg once daily during the 2nd trimester of pregnancy, mean intraindividual values for total rilpivirine Cmax, AUC24h and Cmin values were 21%, 29% and 35% lower, respectively, as compared to postpartum; during the 3rd trimester of pregnancy, Cmax, AUC24h and Cmin values were 20%, 31% and 42% lower, respectively, as compared to postpartum.
K65R-mutationen kan desuden selekteres af abacavir eller didanosin og resultere i nedsat følsomhed for disse stoffer samt for lamivudin, emtricitabin og tenofovir. 
The K65R mutation can also be selected by abacavir or didanosine and results in reduced susceptibility to these agents plus to lamivudine, emtricitabine, and tenofovir.
Seponering af studielægemidlet pga. bivirkninger eller dødd 
Discontinued study drug due to AE or deathd
Hiv 1 indeholder K103N-, Y181C-mutationen eller rilpivirinassocierede substitutioner med resistens over for NNRTI'er var følsomme for tenofovir. 
HIV-1 containing the K103N, Y181C, or rilpivirine-associated substitutions with resistance to NNRTIs were susceptible to tenofovir.
ANALGETIKA Paracetamol/Emtricitabin 
ANALGESICS Paracetamol/Emtricitabine
Resistenstest og/eller historiske resistensdata skal være vejledende for anvendelsen af Eviplera (se pkt. 
Resistance testing and/or historical resistance data should guide the use of Eviplera (see section 5.1).
Emtricitabin-resistente virus med M184V/I-mutationen var krydsresistente over for lamivudin, men beholdt følsomhed for didanosin, stavudin, tenofovir, zalcitabin og zidovudin. 
Emtricitabine-resistant viruses with the M184V/I mutation were cross-resistant to lamivudine, but retained sensitivity to didanosine, stavudine, tenofovir, zalcitabine and zidovudine.
• Gul hud eller gule øjne, kløe eller mavesmerter på grund af betændelse i leveren 
• Yellow skin or eyes, itching or pain in the abdomen (tummy) caused by inflammation of the liver
• Rilpivirin, en non-nukleosid revers transkriptasehæmmer (NNRTI). 
• Rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Hepatitis-eksacerbationer efter seponering af behandling Hos hiv-inficerede patienter, som samtidigt er inficeret med HBV, er der forekommet klinisk og laboratoriemæssig evidens for hepatitis efter seponering af behandlingen (se pkt. 
Exacerbations of hepatitis after discontinuation of treatment In HIV infected patients co-infected with HBV, clinical and laboratory evidence of hepatitis have occurred after discontinuation of treatment (see section 4.4).
Samtidig administration af Eviplera og didanosin anbefales ikke, da det resulterer i en stigning i systemisk eksponering for didanosin på 40-60 %, hvilket kan øge risikoen for didanosinrelaterede bivirkninger (se pkt. 
Co-administration of Eviplera and didanosine is not recommended as it results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
c Der var 17 nye virologiske svigt mellem den primære analyse ved uge 48 og uge 96 (6 patienter med baseline virusbelastning ≤ 100.000 kopier/ml og 11 patienter med baseline virusbelastning > 100.000 kopier/ml). 
c There were 17 new virologic failures between the week 48 primary analysis and week 96 (6 patients with baseline viral load ≤ 100,000 copies/mL and 11 patients with baseline viral load > 100,000 copies/mL).
Behandlingen bør ikke seponeres hos patienter med fremskreden leversygdom eller levercirrose, da hepatitis-eksacerbationer efter behandlingen kan føre til hepatisk dekompensation. 
In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post-treatment exacerbation of hepatitis may lead to hepatic decompensation.
En undergruppeanalyse af virologisk respons (< 50 hiv 1-rna-kopier/ml) ved både uge 48 og uge 96 og virologisk svigt ved baseline virusbelastning (samlede data fra de to kliniske fase III-studier, C209 og C215, for patienter, der fik et baggrundsprogram med emtricitabin/tenofovirdisoproxil) er vist i Tabel 5. 
A subgroup analysis of the virologic response (< 50 HIV-1 RNA copies/mL) at both 48 weeks and 96 weeks, and virologic failure by baseline viral load (pooled data from the two Phase III clinical studies, C209 and C215, for patients receiving the emtricitabine/tenofovir disoproxil background regimen) is presented in Table 5.
osteomalaci (manifesteret som knoglesmerter og i sjældne tilfælde medvirkende årsag til frakturer)3, 5, 8, myopati3, 5 
osteomalacia (manifested as bone pain and infrequently contributing to fractures)3, 5, 8, myopathy3, 5 Renal and urinary disorders Uncommon:
Derfor bør Eviplera kun anvendes hos patienter med let nedsat nyrefunktion, hvis de mulige fordele ved behandlingen anses for at opveje mulige risici (se pkt. 
Therefore, in patients with mild renal impairment Eviplera should only be used if the potential benefits of treatment are considered to outweigh the potential risks (see sections 4.2 and 4.4).
Den gennemsnitlige (% variationskoefficient) emtricitabineksponering steg fra 12 (25 %) µg•t/ml hos patienter med normal nyrefunktion til 20 (6 %) µg•t/ml, 25 (23 %) µg•t/ml og 34 (6 %) µg•t/ml hos patienter med henholdsvis let, moderat og svært nedsat nyrefunktion. 
The mean (%CV) emtricitabine drug exposure increased from 12 (25%) µg•h/mL in patients with normal renal function, to 20 (6%) µg•h/mL, 25 (23%) µg•h/mL and 34 (6%) µg•h/mL, in patients with mild, moderate and severe renal impairment, respectively.
NARKOTISKE ANALGETIKA Methadon/Emtricitabin 
NARCOTIC ANALGESICS Methadone/Emtricitabine
Raltegravir (400 mg to gange dagligt)/ Tenofovirdisoproxil 
Raltegravir (400 mg twice daily)/ Tenofovir disoproxil
Emtricitabin-resistente vira med M184V/I-substitutionen var krydsresistente over for lamivudin, men bibeholdt følsomhed for didanosin, stavudin, tenofovir og zidovudin. 
Emtricitabine-resistant viruses with the M184V/I substitution were cross-resistant to lamivudine, but retained sensitivity to didanosine, stavudine, tenofovir, and zidovudine.
Ingen dosisjustering af Eviplera er nødvendig hos patienter med let nedsat eller moderat nedsat leverfunktion. 
No dose adjustment of Eviplera is required in patients with mild or moderate hepatic impairment.
Alvorlige hudreaktioner med systemiske symptomer er blevet rapporteret efter markedsføring af Eviplera, herunder udslæt ledsaget af feber, blærer, konjunktivitis, angioødem, forhøjede leverfunktionsprøver og/eller eosinofili (se pkt. 
Severe skin reactions with systemic symptoms have been reported during post-marketing experience with Eviplera, including rashes accompanied by fever, blisters, conjunctivitis, angioedema, elevated liver function tests, and/or eosinophilia (see section 4.4).
• Smerter, mavesmerter eller mavebesvær, oppustethed, mundtørhed 
• Pain, stomach pain or discomfort, feeling bloated, dry mouth
ANTIDIABETIKA Metformin/Emtricitabin 
ANTIDIABETICS Metformin/Emtricitabine
Eviplera bør ikke indgives samtidig med rilpivirinhydrochlorid, medmindre dosisjustering er nødvendig i forbindelse med samtidig administration af rifabutin (se pkt. 
Eviplera should not be administered concomitantly with rilpivirine hydrochloride unless needed for dose adjustment with rifabutin (see section 4.2).
d Der var 10 nye virologiske svigt mellem den primære analyse ved uge 48 og uge 96 (3 patienter med baseline virusbelastning ≤ 100.000 kopier/ml og 7 patienter med baseline virusbelastning > 100.000 kopier/ml). 
d There were 10 new virologic failures between the week 48 primary analysis and week 96 (3 patients with baseline viral load ≤ 100,000 copies/mL and 7 patients with baseline viral load > 100,000 copies/mL).
Derfor bør Eviplera kun anvendes hos patienter med let nedsat nyrefunktion, hvis de mulige fordele ved behandlingen opvejer mulige risici (se pkt. 
Therefore, in patients with mild renal impairment Eviplera should only be used if the potential benefits of treatment outweigh the potential risks (see sections 4.4 and 5.2).
IMMUNOSUPPRESIVA Tacrolimus/Tenofovirdisoproxil/Emtricitabin Tacrolimus: 
IMMUNOSUPPRESSANTS Tacrolimus/Tenofovir disoproxil/ Emtricitabine
Emtricitabins farmakokinetik er ikke blevet undersøgt hos patienter med forskellige grader af leverinsufficiens. 
The pharmacokinetics of emtricitabine has not been studied in patients with varying degrees of hepatic insufficiency.
HMG CO-A-REDUKTASEHÆMMERE Atorvastatin/Emtricitabin 
HMG CO-A REDUCTASE INHIBITORS Atorvastatin/Emtricitabine
Eviplera bør administreres med forsigtighed til ældre patienter (se pkt. 
Eviplera should be administered with caution to elderly patients (see sections 4.4 and 5.2).
Didanosin Samtidig administration af Eviplera og didanosin anbefales ikke (se pkt. 
Didanosine The co-administration of Eviplera and didanosine is not recommended (see section 4.4 and Table 1).
Virologisk svigtc 
Virologic failurec
Sildenafil (50 mg enkeltdosis)/Rilpivirin1 
Sildenafil (50 mg single dose)/ Rilpivirine1
Samtidig administration af Eviplera og didanosin frarådes, da eksponering for didanosin er signifikant forhøjet efter samtidig administration af tenofovirdisoproxil, hvilket kan øge risikoen for didanosinrelaterede bivirkninger (se pkt. 
Co-administration of Eviplera and didanosine is not recommended since exposure to didanosine is significantly increased following co-administration with tenofovir disoproxil, which may increase the risk of didanosine-related adverse reactions (see section 4.5).
Eviplera indeholder lactose og Sunset yellow FCF aluminium lak (E110) 
Eviplera contains lactose and sunset yellow aluminium lake (E110)
Hvis en patient kaster op inden for 4 timer efter at have taget Eviplera, skal der tages en ny Evipleratablet sammen med mad. 
If a patient vomits within 4 hours of taking Eviplera another Eviplera tablet should be taken with food.
Eviplera skal tages sammen med mad (se pkt. 
Eviplera must be taken with food (see section 5.2).
forhøjede aminotransferaser (ASAT og/eller ALAT)1, 2, 3 
Very common: increased transaminases (AST and/or ALT)1, 2, 3 Common:
H2-antagonister bør ikke tages i et program med indtagelse to gange dagligt. 
H2-antagonists should not be taken in a twice a day regimen.
Interaktion er ikke undersøgt med Eviplera. 
Interaction not studied with Eviplera.
Procentdel af patienter med samtidig infektion med HBV/HCV 
HIV/HBV or HCV co-infected patients
Eviplera 200 mg/25 mg/245 mg filmovertrukne tabletter emtricitabin/rilpivirin/tenofovirdisoproxil 
Eviplera 200 mg/25 mg/245 mg film-coated tablets emtricitabine/rilpivirine/tenofovir disoproxil
Når De snart ikke har mere af Eviplera, skal De bede om mere fra lægen eller på apoteket. 
When your supply of Eviplera starts to run low, get more from your doctor or pharmacist.
Rilpivirinhydrochlorid er ikke undersøgt hos patienter med svært nedsat leverfunktion (CPT score C). 
Rilpivirine hydrochloride has not been studied in patients with severe hepatic impairment (CPT Score C).
Hos patienter med virusbelastning ved baseline > 100.000 kop ier/ml (n = 44) 
In patients with BL VL1 > 100,000 copies/mL (n = 44)
Tenofovirs gennemsnitlige (% variationskoefficient) Cmax- og AUC0-∞-værdier var henholdsvis 223 (34,8 %) ng/ml og 2.050 (50,8 %) ng•t/ml hos probander med normal leverfunktion sammenlignet med 289 (46,0 %) ng/ml og 2.310 (43,5 %) ng•t/ml hos probander med moderat nedsat leverfunktion og 305 (24,8 %) ng/ml og 2.740 (44,0 %) ng•t/ml hos probander med svært nedsat leverfunktion. 
The mean (%CV) tenofovir Cmax and AUC0-∞ values were 223 (34.8%) ng/mL and 2,050 (50.8%) ng•h/mL, respectively, in normal subjects compared with 289 (46.0%) ng/mL and 2,310 (43.5%) ng•h/mL in subjects with moderate hepatic impairment, and 305 (24.8%) ng/mL and 2,740 (44.0%) ng•h/mL in subjects with severe hepatic impairment.
• Fortæl Deres læge, hvis De lider af allergi over for Sunset yellow FCF aluminium lak 
• Tell your doctor if you have an allergy to sunset yellow aluminium lake (E110).
Det er blevet observeret, at samtidig administration af Eviplera og lægemidler, der hæmmer CYP3A enzymaktiviten kan forhøje plasmakoncentrationer af rilpivirin. 
Co-administration of Eviplera with medicinal products that inhibit CYP3A enzyme activity has been observed to increase rilpivirine plasma concentrations.
Det er blevet observeret, at samtidig administration af Eviplera og lægemidler, der inducerer CYP3A, nedsætter plasmakoncentrationer af rilpivirin, hvilket kunne medføre tab af den terapeutiske virkning af Eviplera (se pkt. 
Co-administration of Eviplera and medicinal products that induce CYP3A has been observed to decrease the plasma concentrations of rilpivirine which could potentially lead to loss of therapeutic effect of Eviplera (see section 4.3).
Antimykobakterielle midler Rifabutin/Emtricitabin 
Antimycobacterials Rifabutin/Emtricitabine
 Hvis De tror, De har laktatacidose, skal De straks fortælle det til lægen. 
 If you think you may have lactic acidosis, tell your doctor immediately.
Antiretrovirale lægemidler 
Antiretrovirals
Antivirale midler mod herpesvirus Famciclovir/Emtricitabin 
Herpesvirus antiviral agents Famciclovir/Emtricitabine
Da tenofovirdisoproxil kan forårsage nyretoksicitet, anbefales tæt monitorering af nyrefunktionen hos alle patienter med nedsat nyrefunktion, som behandles med Eviplera (se pkt. 
Since tenofovir disoproxil can cause renal toxicity, close monitoring of renal function is recommended in any patient with renal impairment treated with Eviplera (see sections 4.2, 4.4 and 5.2).
Maraviroc/Rilpivirin 
Maraviroc/Rilpivirine
hepatitis3, steatosis hepatis3 Hud og subkutane væv Meget almindelig: 
hepatitis3, hepatic steatosis3
I den samlede resistensanalyse af de kliniske fase III-studier C209 og C215 ved uge 96 af patienter, der fik emtricitabin/tenofovirdisoproxil + rilpivirinhydrochlorid, var der 78 patienter med virologisk svigt, hvor information om genotype-resistens var tilgængelig for 71. 
In the week 96 pooled resistance analysis for patients receiving emtricitabine/tenofovir disoproxil + rilpivirine hydrochloride in the Phase III clinical studies C209 and C215, there were 78 virologic failure patients with genotypic resistance information available for 71 of those patients.
• Tenofovirdisoproxil, en nukleotid revers transkriptasehæmmer (NtRTI). 
• Tenofovir disoproxil, a nucleotide reverse transcriptase inhibitor (NtRTI).
Sofosbuvir/velpatasvir/voxilaprevir (400 mg/100 mg/100 mg + 100 mg én gang dagligt)5/Rilpivirin/emtricitabin (25 mg/200 mg én gang dagligt)6 
Sofosbuvir/Velpatasvir/ Voxilaprevir (400 mg/100 mg/ 100 mg + 100 mg once daily)5/ Rilpivirine/Emtricitabine (25 mg/200 mg once daily)6
Nyrefunktionen bør monitoreres hos patienter, som får Eviplera (se pkt. 
Monitoring of renal function is recommended for patients receiving Eviplera (see section 4.4).
Indlægsseddel: Information til brugeren Eviplera 200 mg/25 mg/245 mg filmovertrukne tabletter emtricitabin/rilpivirin/tenofovirdisoproxil 
Package leaflet: Information for the user Eviplera 200 mg/25 mg/245 mg film-coated tablets emtricitabine/rilpivirine/tenofovir disoproxil
Antimykotika Ketoconazol/Emtricitabin 
Antifungals Ketoconazole/Emtricitabine
ETIKETTERING PÅ TABLETBEHOLDER OG KARTON 
BOTTLE AND CARTON LABELLING
Tenofovir udviste antiviral aktivitet i cellekultur mod hiv 1 undertyper A, B, C, D, E, F, G og O (EC50-værdier var i intervallet fra 0,5 til 2,2 µM) og stammespecifik aktivitet mod hiv 2 (EC50-værdier var i intervallet fra 1,6 til 5,5 µM). 
Tenofovir displayed antiviral activity in cell culture against HIV-1 subtype A, B, C, D, E, F, G, and O (EC50 values ranged from 0.5 to 2.2 µM) and strain specific activity against HIV-2 (EC50 values ranged from 1.6 to 5.5 µM).
Darunavir (800 mg én gang dagligt)/Ritonavir (100 mg én gang dagligt)/Rilpivirin1 
Darunavir (800 mg once daily)/ Ritonavir (100 mg once daily)/ Rilpivirine1
Prækliniske data for rilpivirinhydrochlorid viser ingen speciel risiko for mennesker vurderet ud fra studier af sikkerhedsfarmakologi, lægemiddeldisposition, genotoksicitet, karcinogenicitet samt reproduktions- og udviklingstoksicitet. 
Non-clinical data on rilpivirine hydrochloride reveal no special hazard for humans based on studies of safety pharmacology, drug disposition, genotoxicity, carcinogenic potential, and toxicity to reproduction and development.
forhøjet pancreasamylase2, opkastning1, 2, 3, diarré1, 3, kvalme1, 2, 3 
Very common: increased pancreatic amylase2, vomiting1, 2, 3, diarrhoea1, 3, nausea1, 2, 3
Ikke almindelig: angioødem1, 3, 6, alvorlige hudreaktioner med systemiske symptomer7 Knogler, led, muskler og bindevæv 
angioedema1, 3, 6, severe skin reactions with systemic symptoms7 Musculoskeletal and connective tissue disorders Very common: elevated creatine kinase1
Interaktion er ikke undersøgt med nogen af komponenterne fra Eviplera. 
Interaction not studied with any of the components of Eviplera.
Emtricitabin viste antiviral aktivitet i cellekultur mod hiv 1 undertypen A, B, C, D, E, F og G (EC50-værdier var i intervallet fra 0,007 til 0,075 µM) og viste stammespecifik aktivitet mod hiv 2 (EC50-værdier var i intervallet fra 0,007 til 1,5 µM). 
Emtricitabine displayed antiviral activity in cell culture against HIV-1 subtype A, B, C, D, E, F, and G (EC50 values ranged from 0.007 to 0.075 µM) and showed strain specific activity against HIV-2 (EC50 values ranged from 0.007 to 1.5 µM).
Yderligere behandlingstiltag bør, hvis muligt, bygge på de kliniske tegn eller følge anbefalingerne fra Giftlinjen. 
Further management should be as clinically indicated or as recommended by the national poisons centre, where available.
Behandlingsnaive hiv 1-inficerede patienter 
Treatment-naïve HIV-1 infected patients
Samtidig administration af Eviplera og didanosin frarådes (se pkt. 
Co-administration of Eviplera and didanosine is not recommended (see section 4.4).
Seponering af behandlingen med Eviplera hos hiv-inficerede patienter, der samtidig er inficeret med HBV, kan forekomme i forbindelse med svær, akut eksacerbation af hepatitis. 
Discontinuation of Eviplera therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis.
• Bevægelsesbesvær 
• Difficulty with movement
I behandlingsnaive hiv 1-inficerede patienter 
In treatment-naïve HIV-1 infected patients
Raltegravir/Rilpivirin 
Raltegravir/Rilpivirine
Induktionsvirkningen faldt, og rilpivirin-koncentrationerne begyndte at normaliseres på grund af reduktion i efavirenzplasmaniveauet. 
Due to the decline in efavirenz plasma levels, the inductive effect decreased and rilpivirine concentrations started to normalise.
Nervesystemet Meget almindelig: 
Immune system disorders Common: